Benaroya Research Institute Welcomes New Board Members
SEATTLE (Feb. 8, 2013) – Benaroya Research Institute at Virginia Mason (BRI) announced three new members to its Board of Directors: Rebecca Campbell, Michael Gallatin, PhD, and Ann Sobil. Robert Lemon is also joining the board as an emeritus director for 2013.
Rebecca Campbell is co-owner of two international information technology companies. She also is co-founder of a family foundation, Cure 4 Type 1, to raise and disburse funding for Type 1 diabetes research. She is a board member of the Seattle guild of the JDRF as well.
Michael Gallatin, PhD, was a co-founder of Stromedix, which focused on novel treatments for chronic fibrotic diseases, and Calistoga Pharmaceuticals, which developed therapies for cancer and inflammatory diseases, prior to their acquisitions by Biogen-IDEC and Gilead Sciences respectively. He was also vice president and scientific director of ICOS Corporation. Dr. Gallatin has more than 30 years in immunology, oncology and cell biology research and has served on numerous boards.
Ann Sobil is general sales manager of KIRO Television. She has more than 20 years’ experience in sales strategy and development for multiple television stations. Sobil has served as executive board member, King/Snohomish County American Red Cross and board member, Seattle Sports Commission. She is currently a board member of The Bellevue Chamber of Commerce and the Eastside Business Roundtable.
Robert Lemon is a retired managing partner of Accenture LLP. He joined the BRI Board in 2003 and served two terms as Board of Directors Chair, 2008-2012. Lemon is a member of the Virginia Mason Medical Center and Health Systems boards as well as Northwest Kidney Centers and an Advisory Council at the University of Notre Dame.
About Benaroya Research Institute at Virginia Mason
Benaroya Research Institute at Virginia Mason (BRI), founded in 1956, is an international leader in immune system and autoimmune disease research, translating discoveries to real life applications. Autoimmune diseases happen when the immune system, designed to protect the body, attacks it instead. BRI is one of the few research institutes in the world dedicated to discovering causes and cures to eliminate autoimmune diseases such as Type 1 diabetes, multiple sclerosis, arthritis and many others. Visit BenaroyaResearch.org or Facebook/BenaroyaResearch for more information about BRI, clinical studies and the more than 80 different types of autoimmune diseases.
BRI employs more than 250 scientists, physician researchers and staff with a research volume of more than $39 million in 2012, including grants from the National Institutes of Health, the National Science Foundation, the U.S. Department of Defense, JDRF, the American Heart Association and others.
BRI Director of Communications